MX2012008861A - Composicion farmaceutica con actividad antiobesidad que comprende una premezcla de orlistat puro y proceso de preparacion. - Google Patents

Composicion farmaceutica con actividad antiobesidad que comprende una premezcla de orlistat puro y proceso de preparacion.

Info

Publication number
MX2012008861A
MX2012008861A MX2012008861A MX2012008861A MX2012008861A MX 2012008861 A MX2012008861 A MX 2012008861A MX 2012008861 A MX2012008861 A MX 2012008861A MX 2012008861 A MX2012008861 A MX 2012008861A MX 2012008861 A MX2012008861 A MX 2012008861A
Authority
MX
Mexico
Prior art keywords
premixture
pharmaceutical composition
orlistat
obesity activity
compositions
Prior art date
Application number
MX2012008861A
Other languages
English (en)
Inventor
Mario Atilio Los
Original Assignee
Bago Sa Labor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43126897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012008861(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bago Sa Labor filed Critical Bago Sa Labor
Publication of MX2012008861A publication Critical patent/MX2012008861A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones farmacéuticas con actividad antiobesidad de acción periférica que comprenden una premezcla formada por orlistat puro como principio activo y otros componentes que confieren a la premezcia estabilidad y propiedades físicas adecuadas para la elaboración simple de composiciones de uso oral con flexibilidad posológica conveniente; y opcionalmente agentes espesantes, saborizantes y colorantes necesarios. También se proporciona un método para elaborar dichas composiciones. El contenido de orlistat en la premezcla es inferior al 20% del peso total de la masa siendo de preferencia entre 12 y 17%. La composición farmacéutica se puede formular indistintamente a partir de la premezcla tanto de comprimidos ranurados como en forma de polvo para la suspensión.
MX2012008861A 2010-02-01 2010-02-01 Composicion farmaceutica con actividad antiobesidad que comprende una premezcla de orlistat puro y proceso de preparacion. MX2012008861A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/000579 WO2011091816A1 (en) 2010-02-01 2010-02-01 Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process

Publications (1)

Publication Number Publication Date
MX2012008861A true MX2012008861A (es) 2013-08-29

Family

ID=43126897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008861A MX2012008861A (es) 2010-02-01 2010-02-01 Composicion farmaceutica con actividad antiobesidad que comprende una premezcla de orlistat puro y proceso de preparacion.

Country Status (12)

Country Link
US (1) US8685449B2 (es)
EP (1) EP2531172B1 (es)
CN (1) CN102740831B (es)
AR (1) AR078940A1 (es)
BR (1) BR112012018696B1 (es)
CL (1) CL2012002077A1 (es)
ES (1) ES2609018T3 (es)
MX (1) MX2012008861A (es)
PL (1) PL2531172T3 (es)
UA (1) UA107369C2 (es)
WO (1) WO2011091816A1 (es)
ZA (1) ZA201205769B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552168B (zh) * 2012-01-31 2013-08-07 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
CN106309565A (zh) * 2015-06-29 2017-01-11 北京海吉星医疗科技有限公司 一种贞芪扶正缓释滴丸及其制备方法
RU2762552C2 (ru) * 2020-10-05 2021-12-21 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция оксиэтиламмония метилфеноксиацетата

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI54811C (fi) 1972-06-03 1979-03-12 Vega Jose Manuel Regife Foerfarande foer tillvaratagning och rening av zink fraon zinkhaltiga loesningar
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2009044380A2 (en) * 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
PL216542B1 (pl) * 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku

Also Published As

Publication number Publication date
CN102740831B (zh) 2015-01-28
WO2011091816A1 (en) 2011-08-04
EP2531172A1 (en) 2012-12-12
ES2609018T3 (es) 2017-04-18
UA107369C2 (en) 2014-12-25
EP2531172B1 (en) 2016-10-12
US8685449B2 (en) 2014-04-01
PL2531172T3 (pl) 2017-07-31
BR112012018696B1 (pt) 2019-07-02
ZA201205769B (en) 2013-04-24
BR112012018696A2 (pt) 2016-05-03
US20120294941A1 (en) 2012-11-22
CL2012002077A1 (es) 2012-12-07
AR078940A1 (es) 2011-12-14
CN102740831A (zh) 2012-10-17

Similar Documents

Publication Publication Date Title
EP3626253A3 (en) Stable formulations of linaclotide
TN2012000362A1 (en) Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
NZ601738A (en) Apixaban formulations
WO2015120110A3 (en) Novel pharmaceutical formulations
PH12015500633A1 (en) Method for preparing imp fermented broth or glutamic acid fermented broth as raw material for preparation of natural flavor
MX354102B (es) Derivados de bencimidazol-prolina.
SG196810A1 (en) Controlled release pharmaceutical or foodformulation and process for its preparation
NZ707551A (en) Prostacyclin compositions and methods for using the same
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
TN2012000595A1 (en) Substituted triazolopyridines
JO2831B1 (en) Quinclidine carbonate derivatives and pharmaceutical compounds
PH12015500611A1 (en) Oral care composition
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
PH12014502619A1 (en) Novel dosage and formulation
MX2012008861A (es) Composicion farmaceutica con actividad antiobesidad que comprende una premezcla de orlistat puro y proceso de preparacion.
MX2013013079A (es) Composiciones que comprenden un agente antibacterial y tazobactam.
IN2013MU01177A (es)
NZ704342A (en) Compositions comprising spicamycin derivatives and methods of use thereof
RS53835B1 (en) PHARMACEUTICAL COMPOSITION WITH ANTIMICROBIC ACTION AND FOR ACCELERATED HEALING, FOR EXTERNAL ADMINISTRATION, PROCESSES FOR ITS ACQUISITION
WO2011119649A3 (en) Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs
WO2011034514A3 (en) Stable micronized granules having high solubility

Legal Events

Date Code Title Description
FG Grant or registration